Amgen pleads guilty to misbranding charges, will pay $762 mln
NEW YORK Dec 18 (Reuters) - Amgen Inc pleaded guilty in a federal court in New York on Tuesday to misbranding its Aranesp anemia drug and agreed to pay $762 million in a civil settlement and criminal fines.
The company, the largest in the global biotechnology sector, had already set aside funds it expected to have to pay as a result of federal and state investigations as well as nearly a dozen civil whistleblower lawsuits.
Federal prosecutors said in court that the company was paying a $612 million civil settlement, a $14 million forfeiture, and a $136 million criminal fine.
Amgen entered the guilty plea, but no sentence has been issued.
Aranesp is one of Amgen's largest drugs and had sales of $2.3 billion in 2011.
A spokeswoman for the company, based in Thousand Oaks, California, declined to give an immediate comment.
(Writing by Caroline Humer; Editing by Lisa Von Ahn)
- Sunken Korea ferry relatives give DNA swabs to help identify dead |
- Vice-principal of South Korea school in ferry disaster commits suicide |
- Special Report: How the U.S. made its Putin problem worse
- Death toll climbs to at least 13 in worst tragedy on Everest |
- All 338 Korean students, teachers rescued from sinking ferry - school official